Why the study?
Does inhibiting Nox2 ROS production improve diaphragm tissue microtubule organization, stiffness, and muscle/respiratory function in dystrophic mice?
Does inhibiting Nox2 ROS production improve diaphragm tissue microtubule organization, stiffness, and muscle/respiratory function in dystrophic mice?
Inhibiting Nox2 ROS production improves force and respiratory function in dystrophic diaphragms, establishing Nox2 as a potential therapeutic target in Duchenne muscular dystrophy.
Nox2 ROS may drive microtubule changes and stiffness in dystrophic muscle; leaves open whether targeting this axis improves patient outcomes.
Skeletal muscle from mdx mice is characterized by increased Nox2 ROS, altered microtubule network, increased muscle stiffness, and decreased muscle/respiratory function. While microtubule de-tyrosination has been suggested to increase stiffness and Nox2 ROS production in isolated single myofibers, its role in altering tissue stiffness and muscle function has not been established. Because Nox2 ROS production is upregulated prior to microtubule network alterations and ROS affect microtubule formation, we investigated the role of Nox2 ROS in diaphragm tissue microtubule organization, stiffness and muscle/respiratory function. Eliminating Nox2 ROS prevents microtubule disorganization and reduces fibrosis and muscle stiffness in mdx diaphragm. Fibrosis accounts for the majority of variance in diaphragm stiffness and decreased function, implicating altered extracellular matrix and not microtubule de-tyrosination as a modulator of diaphragm tissue function. Ultimately, inhibiting Nox2 ROS production increased force and respiratory function in dystrophic diaphragm, establishing Nox2 as a potential therapeutic target in Duchenne muscular dystrophy.
No takes yet. Share an insight, caveat, or question.
Loehr et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: